Respiratory Reviews in Asthma 2013.
10.4046/trd.2014.76.3.105
- Author:
Tae Hyung KIM
1
Author Information
1. Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Seoul, Korea. drterry@hanyang.ac.kr
- Publication Type:Review
- Keywords:
Asthma;
Phenotype;
Pharmacogenetics;
Therapeutics
- MeSH:
Anti-Bacterial Agents;
Antibodies, Monoclonal;
Asthma*;
Classification;
Disease Progression;
Disease Susceptibility;
Genome;
Genome-Wide Association Study;
Mortality;
Pharmacogenetics;
Phenotype
- From:Tuberculosis and Respiratory Diseases
2014;76(3):105-113
- CountryRepublic of Korea
- Language:English
-
Abstract:
From January 2012 up until March 2013, many articles with huge clinical importance in asthma were published based on large numbered clinical trials or meta-analysis. The main subjects of these studies were the new therapeutic plan based on the asthma phenotype or efficacy along with the safety issues regarding the current treatment guidelines. For efficacy and safety issues, inhaled corticosteroid tapering strategy or continued long-acting beta agonists use was the major concern. As new therapeutic trials, monoclonal antibodies or macrolide antibiotics based on inflammatory phenotypes have been under investigation, with promising preliminary results. There were other issues on the disease susceptibility or genetic background of asthma, particularly for the "severe asthma" phenotype. In the era of genome and pharmacogenetics, there have been extensive studies to identify susceptible candidate genes based on the results of genome wide association studies (GWAS). However, for severe asthma, which is where most of the mortality or medical costs develop, it is very unclear. Moreover, there have been some efforts to find important genetic information in order to predict the possible disease progression, but with few significant results up until now. In conclusion, there are new on-going aspects in the phenotypic classification of asthma and therapeutic strategy according to the phenotypic variations. With more pharmacogenomic information and clear identification of the "severe asthma" group even before disease progression from GWAS data, more adequate and individualized therapeutic strategy could be realized in the future.
